These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
242 related items for PubMed ID: 17302732
1. Soluble apoptosis molecules in primary biliary cirrhosis: analysis and commitment of the Fas and tumour necrosis factor-related apoptosis-inducing ligand systems in comparison with chronic hepatitis C. Pelli N, Floreani A, Torre F, Delfino A, Baragiotta A, Contini P, Basso M, Picciotto A. Clin Exp Immunol; 2007 Apr; 148(1):85-9. PubMed ID: 17302732 [Abstract] [Full Text] [Related]
2. Role of soluble tumor necrosis factor-related apoptosis-inducing ligand concentrations after stem cell transplantation. Nomura S, Ishii K, Inami N, Uoshima N, Ishida H, Yoshihara T, Kitayama H, Hayashi K. Transpl Immunol; 2007 Nov; 18(2):115-21. PubMed ID: 18005854 [Abstract] [Full Text] [Related]
3. Characterisation of TNF-related apoptosis-inducing ligand in peripheral blood in patients with primary biliary cirrhosis. Liang Y, Yang Z, Li C, Zhu Y, Zhang L, Zhong R. Clin Exp Med; 2008 Mar; 8(1):1-7. PubMed ID: 18385934 [Abstract] [Full Text] [Related]
4. Circulating levels of soluble apoptosis-related molecules in patients with multiple sclerosis. Moreno M, Sáenz-Cuesta M, Castilló J, Cantó E, Negrotto L, Vidal-Jordana A, Montalban X, Comabella M. J Neuroimmunol; 2013 Oct 15; 263(1-2):152-4. PubMed ID: 23932896 [Abstract] [Full Text] [Related]
5. Markers of cell activation and apoptosis in bone marrow mononuclear cells of patients with autoimmune hepatitis type 1 and primary biliary cirrhosis. Tsikrikoni A, Kyriakou DS, Rigopoulou EI, Alexandrakis MG, Zachou K, Passam F, Dalekos GN. J Hepatol; 2005 Mar 15; 42(3):393-9. PubMed ID: 15710223 [Abstract] [Full Text] [Related]
6. Lipoteichoic acid may affect the pathogenesis of bile duct damage in primary biliary cirrhosis. Haruta I, Hashimoto E, Kato Y, Kikuchi K, Kato H, Yagi J, Uchiyama T, Kobayash M, Shiratori K. Autoimmunity; 2006 Mar 15; 39(2):129-35. PubMed ID: 16698669 [Abstract] [Full Text] [Related]
7. Prognostic Value of Soluble Death Receptor Ligands in Patients with Transitional Cell Carcinoma of Bladder. Ben Bahria-Sediki I, Chebil M, Sampaio C, Martel-Frachet V, Cherif M, Zermani R, Rammeh S, Ben Ammar Gaaied A, Bettaieb A. Urol Int; 2018 Mar 15; 100(4):476-484. PubMed ID: 29719304 [Abstract] [Full Text] [Related]
8. The involvement of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) in atherosclerosis. Michowitz Y, Goldstein E, Roth A, Afek A, Abashidze A, Ben Gal Y, Keren G, George J. J Am Coll Cardiol; 2005 Apr 05; 45(7):1018-24. PubMed ID: 15808757 [Abstract] [Full Text] [Related]
9. Fas / FasL system, IL-1beta expression and apoptosis in chronic HBV and HCV liver disease. Bortolami M, Kotsafti A, Cardin R, Farinati F. J Viral Hepat; 2008 Jul 05; 15(7):515-22. PubMed ID: 18331250 [Abstract] [Full Text] [Related]
12. Clinical significance of serum soluble Fas, Fas ligand and fas in intrahepatic lymphocytes in chronic hepatitis C. Zaki Mel S, Auf FA, Ghawalby NA, Saddal NM. Immunol Invest; 2008 Jul 05; 37(2):163-70. PubMed ID: 18300041 [Abstract] [Full Text] [Related]
13. Involvement of TRAIL and its receptors in viral hepatitis. Mundt B, Kühnel F, Zender L, Paul Y, Tillmann H, Trautwein C, Manns MP, Kubicka S. FASEB J; 2003 Jan 05; 17(1):94-6. PubMed ID: 12475902 [Abstract] [Full Text] [Related]
14. Tumour necrosis factor related apoptosis inducing ligand (TRAIL) induces hepatic steatosis in viral hepatitis and after alcohol intake. Mundt B, Wirth T, Zender L, Waltemathe M, Trautwein C, Manns MP, Kühnel F, Kubicka S. Gut; 2005 Nov 05; 54(11):1590-6. PubMed ID: 16227360 [Abstract] [Full Text] [Related]
15. CD40 activation-induced, Fas-dependent apoptosis and NF-kappaB/AP-1 signaling in human intrahepatic biliary epithelial cells. Afford SC, Ahmed-Choudhury J, Randhawa S, Russell C, Youster J, Crosby HA, Eliopoulos A, Hubscher SG, Young LS, Adams DH. FASEB J; 2001 Nov 05; 15(13):2345-54. PubMed ID: 11689460 [Abstract] [Full Text] [Related]
16. Enhanced apoptosis relates to bile duct loss in primary biliary cirrhosis. Harada K, Ozaki S, Gershwin ME, Nakanuma Y. Hepatology; 1997 Dec 05; 26(6):1399-405. PubMed ID: 9397977 [Abstract] [Full Text] [Related]
17. Treatment with IFNalpha in vivo up-regulates serum-soluble TNF-related apoptosis inducing ligand (sTRAIL) levels and TRAIL mRNA expressions in neutrophils in chronic myelogenous leukemia patients. Tanaka H, Ito T, Kyo T, Kimura A. Eur J Haematol; 2007 May 05; 78(5):389-98. PubMed ID: 17432976 [Abstract] [Full Text] [Related]
18. Involvement of tumor necrosis factor-related apoptosis-inducing ligand and tumor necrosis factor-related apoptosis-inducing ligand receptors in viral hepatic diseases. Saitou Y, Shiraki K, Fuke H, Inoue T, Miyashita K, Yamanaka Y, Yamaguchi Y, Yamamoto N, Ito K, Sugimoto K, Nakano T. Hum Pathol; 2005 Oct 05; 36(10):1066-73. PubMed ID: 16226105 [Abstract] [Full Text] [Related]
19. Thyroid carcinoma cells are resistant to FAS-mediated apoptosis but sensitive to tumor necrosis factor-related apoptosis-inducing ligand. Mitsiades N, Poulaki V, Tseleni-Balafouta S, Koutras DA, Stamenkovic I. Cancer Res; 2000 Aug 01; 60(15):4122-9. PubMed ID: 10945619 [Abstract] [Full Text] [Related]